Suppliers and packagers for generic pharmaceutical drug: epinephrine bitartrate

epinephrine bitartrate

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Baxter Hlthcare Corp	EPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE	epinephrine bitartrate	SOLUTION;INTRAVENOUS	218475	NDA	Baxter Healthcare Corporation	0338-0006-20	20 BAG in 1 CARTON (0338-0006-20) / 250 mL in 1 BAG	2026-03-16
Baxter Hlthcare Corp	EPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE	epinephrine bitartrate	SOLUTION;INTRAVENOUS	218475	NDA	Baxter Healthcare Corporation	0338-0024-20	20 BAG in 1 CARTON (0338-0024-20) / 250 mL in 1 BAG	2025-02-28

Suppliers and packagers for generic pharmaceutical drug: epinephrine bitartrate

Last updated: May 24, 2026

Epinephrine Bitartrate Suppliers (API and Finished Dosage Forms): Who Provides the Drug for US and Global Markets?

Epinephrine bitartrate is sourced from a mix of chemical/API manufacturers and contract manufacturers supplying US-labeled injection products. Supplier availability varies by strength, container (single-dose vs multidose), and regulatory status (FDA approval and inspections for sterile manufacturing).

Which companies supply epinephrine bitartrate API for manufacturers and CDMOs?

API supply channels

• API manufacturers: produce epinephrine bitartrate (active pharmaceutical ingredient) for downstream sterile fill-finish.
• Intermediates and chemical suppliers: sell upstream materials used to manufacture epinephrine bitartrate, typically feeding specialized API plants.
• Importers/wholesalers: distribute API under their own catalog or through approved supply chains for finished-dose producers.

Key practical filters that determine “real” supplier viability

• Sterile drug supply chains generally require cGMP-compliant API with validated impurity profiles for parenteral use.
• Suppliers must support DMF (Drug Master File) or full API documentation pathways used by finished-dose applicants and line extensions.
• Audit readiness for sterile and high-control APIs is a gating item in supplier qualification for hospitals and government tenders.

What suppliers provide FDA-approved epinephrine bitartrate injection products (1 mg/mL or equivalent)?

Epinephrine bitartrate is commonly supplied as sterile injection for emergency use. Finished-dose availability is usually concentrated among:

• US sterile injectables manufacturers
• Global sterile injectables CDMOs supplying US labels via private label or contract production
• Distributor networks that source from approved manufacturing sites and maintain lot-level traceability

How to map suppliers to market reality Finished-dose supplier identification is tied to:

• FDA product listing and labeler (who holds marketing authorization for the NDC)
• Manufacturing site shown on labeling or through regulatory filings
• Supply chain certifications for sterile manufacture (sterility assurance, environmental monitoring, endotoxin controls)

How do epinephrine bitartrate supply chains differ by dosage form and packaging?

Supply risk and supplier count differ by:

• Dose strength: concentration drives whether suppliers can compete on cost and documentation.
• Container: vial vs prefilled syringe impacts compatibility, leachables studies, and fill-finish tooling.
• Closure system: rubber stoppers and seals are major drivers of qualification timelines for parenteral injectables.
• Storage requirements: cold-chain is less typical for epinephrine bitartrate injections than for biologics, but stability and light protection still matter.

What regulatory status constraints affect supplier selection for epinephrine bitartrate?

US (FDA)

• Finished products must be manufactured under cGMP.
• Sterile products require robust controls for sterility and microbiological quality.
• API supply typically requires documentation consistent with approved submissions.

EU/UK

• Finished products must comply with GMP under EU/UK regimes.
• Changes to manufacturing sites or specifications trigger variation or post-approval reporting in most cases.

Operational implication A supplier that can sell API may not qualify for sterile-ready finished-dose supply without validated sterile-chain documentation and inspection history.

Which manufacturing regions are most active for epinephrine bitartrate supply?

Typical activity concentrates in:

• China and India for chemical/API manufacture and some sterile intermediates
• US and EU for sterile fill-finish and branded/gov-compliant finished dosage production
• Middle-tier CDMOs in India, Europe, and North America for sterile manufacturing under contract

Supplier qualification usually depends on inspection outcomes, batch documentation maturity, and the ability to support regulatory audits.

How many suppliers exist for epinephrine bitartrate, and how fragmented is the market?

The market is generally fragmented by finished-dose NDCs more than by API itself.

• Many API plants exist globally, but only a subset feed approved sterile injection products.
• Finished-dose supply is constrained by sterile capacity and regulatory readiness, not solely by API availability.

What contract manufacturing and sourcing models are used for epinephrine bitartrate injections?

Common sourcing structures:

• Branded holder to sterile CDMO: holder provides specs and regulatory strategy; CDMO runs sterile fill-finish.
• Generic or distributor to CDMO: distributor/labeler manages filings; CDMO supplies sterile drug substance-to-product integration where applicable.
• API-to-finished integration: for some manufacturers, API procurement is followed by internal sterile manufacturing. This is less common for small labelers.

What “supply failure points” matter most for epinephrine bitartrate availability?

1. API sourcing continuity (plant downtime, raw material availability, impurity excursions).
2. Sterile fill-finish capacity (line availability, QC staffing, batch release delays).
3. Container-closure qualification (stopper/leaker events, change control delays).
4. Regulatory documentation bottlenecks (DMF cross-referencing, change reporting).
5. Lot-level release and distribution constraints (shipping windows, shelf-life management).

How does epinephrine bitartrate supplier selection compare with competing epinephrine products (e.g., hydrochloride)?

Epinephrine bitartrate supply differs from hydrochloride mainly by:

• Salt form compatibility for formulation and impurity profile targets
• Specific supplier qualification for parenteral-grade salt and sterile readiness
• Different spec sheets used for regulatory filings and stability programs

In practice, many sterile manufacturers have established capability for one salt form and qualify the other only for specific programs due to analytical and formulation validation overhead.

What supplier documentation should procurement require for epinephrine bitartrate?

For finished-dose injectables and sterile-ready API, procurement typically requests:

• Certificate of Analysis (CoA) and batch-specific impurity/degradation data
• GMP compliance statements for the manufacturing site
• Regulatory dossier alignment (DMF or equivalent documentation for API)
• Sterility assurance and endotoxin control evidence for finished sterile product
• Traceability documentation (lot genealogy, chain-of-custody)

Key Takeaways

• Epinephrine bitartrate supply splits into API manufacturers and sterile injection finished-dose suppliers/CDMOs.
• Finished-dose supplier “fit” is driven by sterile manufacturing readiness and regulatory documentation, not just API availability.
• Procurement should prioritize suppliers that can support lot traceability, parenteral specs, and cGMP/sterility documentation for the specific NDC strength and container configuration.

FAQs

1. How do I identify the true manufacturer behind an epinephrine bitartrate NDC labeler?
2. What documentation is required to qualify an epinephrine bitartrate API supplier for sterile injectables?
3. Do epinephrine bitartrate and epinephrine hydrochloride injection suppliers overlap in production lines?
4. What are the typical causes of epinephrine bitartrate injection backorders at the finished-dose level?
5. How should procurement structure supplier qualification for container-closure changes in epinephrine bitartrate vials?

References (APA)

1. US Food and Drug Administration. (n.d.). Drug Approval Reports and FDA resources for product labeling and cGMP oversight. FDA. https://www.fda.gov/
2. US Food and Drug Administration. (n.d.). Drugs@FDA database. FDA. https://www.accessdata.fda.gov/scripts/cder/daf/
3. FDA. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data